Voyager Therapeutics (VYGR) Other financing activities (2017 - 2026)
Voyager Therapeutics (VYGR) reported Other financing activities of $294000.0 for Q1 2026, up 258.54% on a YoY basis from $82000.0 in Q1 2025, and up 276.05% sequentially from -$167000.0 in Q4 2025.
Voyager Therapeutics (VYGR) Other financing activities (2017 - 2026) Analysis & Trends
Voyager Therapeutics (VYGR) has 10 years of Other financing activities data on file, last reported at $294000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities rose 258.54% year-over-year to $294000.0; the trailing twelve-month figure through Mar 2026 stood at $479000.0 (up 22.19% YoY), and the FY2025 full-year result was $267000.0, down 31.19% from the prior year.
- Other financing activities climbed to $294000.0 in Q1 2026, from -$167000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $1.2 million in Q2 2023 to a low of -$167000.0 in Q4 2025.
- A 5-year average of $214375.0 and a median of $80000.0 in 2024 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities jumped 2666.67% in 2023 and sank 1092.86% in 2025, its largest moves.
- Tracing VYGR's Other financing activities over 5 years: stood at $27000.0 in 2022, then retreated by 14.81% to $23000.0 in 2023, then tumbled by 160.87% to -$14000.0 in 2024, then slumped by 1092.86% to -$167000.0 in 2025, then jumped by 276.05% to $294000.0 in 2026.
- Business Quant data shows VYGR's Other financing activities at $294000.0 in Q1 2026, -$167000.0 in Q4 2025, and $352000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Voyager Therapeutics | 183.84 Mn | 42.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 294,000.00 |
| Mar 31, 2026 | 294,000.00 |
| Dec 31, 2025 | -167,000.00 |
| Dec 31, 2025 | -167,000.00 |
| Jun 30, 2025 | 352,000.00 |
| Jun 30, 2025 | 352,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Dec 31, 2024 | -14,000.00 |
| Dec 31, 2024 | -14,000.00 |
| Sep 30, 2024 | -79,000.00 |
| Sep 30, 2024 | -79,000.00 |
| Jun 30, 2024 | 403,000.00 |
| Jun 30, 2024 | 403,000.00 |
| Mar 31, 2024 | 78,000.00 |
| Mar 31, 2024 | 78,000.00 |
| Dec 31, 2023 | 23,000.00 |
| Dec 31, 2023 | 23,000.00 |
| Sep 30, 2023 | 415,000.00 |
| Sep 30, 2023 | 415,000.00 |